- Conditions
- Central Nervous System Diseases, Pediatric Disorder, Body Indication
- Interventions
- Gadopiclenol
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- Up to 23 Months
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lesion in Body Region
- Interventions
- gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Farmington, Connecticut • Chicago, Illinois + 4 more
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- 18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- Gadopiclenol
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- CNS Lesion, Blood Brain Barrier Defect
- Interventions
- gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Panorama City, California • Farmington, Connecticut • Chicago, Illinois + 5 more
- Conditions
- Leptomeningeal Disease
- Interventions
- MRI Scan, VUEWAY, Gadavist
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- CNS Lesion, Blood Brain Barrier Defect
- Interventions
- P03277, Gadobenate dimeglumine, MRI
- Drug · Device
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
- Conditions
- Myocardial Fibrosis
- Interventions
- Elucirem (Gadopiclenol)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Contrast Enhanced Images vs. Non-contrast Images, Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images
- Interventions
- Gadopiclenol, Gadobutrol (Gadavist, BAY86-4875)
- Drug
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Congenital Heart Disease
- Interventions
- Gadopiclenol, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Steno-occlusive Disease
- Interventions
- gadopiclenol, Gadoterate meglumine (Dotarem)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
- Conditions
- Liver Lesion
- Interventions
- Radiology, Gadopiclenol
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York